1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Enfermedades neurodegenerativas: desarrollo de terapias

Enfermedades neurodegenerativas: desarrollo de terapias

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • de Lago E, Moreno-Martet M, Cabranes A, Ramos JA, Fernández-Ruiz J.

    Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects

    Neuropharmacology . 62(7): 2299-2308. Nº de citas: 60

    [doi:10.1016/j.neuropharm.2012.01.030]

  • Valdeolivas S, Satta V, Pertwee RG, Fernández-Ruiz J, Sagredo O.

    Sativex-like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned Rats, an Inflammatory Model of Huntington's Disease: Role of CB1 and CB2 Receptors

    ACS CHEMICAL NEUROSCIENCE . 3(5): 400-406. Nº de citas: 58

    [doi:10.1021/cn200114w]

  • Sagredo O, Pazos MR, Valdeolivas S, Fernandez-Ruiz J.

    Cannabinoids: novel medicines for the treatment of Huntington's disease.

    Recent patents on CNS drug discovery . 7(1): 41-48.

  • Cumella J, Hernández-Folgado L, Girón R, Sánchez E, Morales P, Hurst DP, Gómez-Cañas M, Gómez-Ruiz M, Pinto DC, Goya P, Reggio PH, Martin MI, Fernández-Ruiz J, Silva AM, Jagerovic N.

    Chromenopyrazoles: Non-psychoactive and Selective CB1 Cannabinoid Agonists with Peripheral Antinociceptive Properties

    Chemmedchem . 7(3, SI): 452-463. Nº de citas: 26

    [doi:10.1002/cmdc.201100568]

  • Perucho J, Casarejos MJ, Gomez A, Solano RM, de Yébenes JG, Mena MA.

    Trehalose protects from aggravation of amyloid pathology induced by isoflurane anesthesia in APP(swe) mutant mice.

    CURR ALZHEIMER RES . 9(3): 334-343.

  • Moreno-Martet M, Mestre L, Loría F, Guaza C, Fernández-Ruiz J, de Lago E.

    Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: Relevance for in vitro studies with cannabinoids in motor neuron diseases

    NEUROSCIENCE LETTERS . 508(2): 67-72. Nº de citas: 10

    [doi:10.1016/j.neulet.2011.12.020]

  • Ruiz C, Casarejos MJ, Gomez A, Solano R, de Yebenes JG, Mena MA.

    Protection by glia-conditioned medium in a cell model of Huntington disease.

    PLoS currents . 4: .

    [doi:10.1371/4fbca54a2028b]

  • Solano RM, Casarejos MJ, Gómez A, Perucho J, de Yébenes JG, Mena MA.

    Parkin Null Cortical Neuronal/Glial Cultures are Resistant to Amyloid-beta(1-42) Toxicity: A Role for Autophagy?

    JOURNAL OF ALZHEIMERS DISEASE . 32(1): 57-76. Nº de citas: 11

    [doi:10.3233/JAD-2012-120406]

  • Marco I, Valhondo M, Martín-Fontecha M, Vázquez-Villa H, Del Río J, Planas A, Sagredo O, Ramos JA, Torrecillas IR, Pardo L, Frechilla D, Benhamú B, López-Rodríguez ML.

    New Serotonin 5-HT1A Receptor Agonists with Neuroprotective Effect against Ischemic Cell Damage

    JOURNAL OF MEDICINAL CHEMISTRY . 54(23): 7986-7999. Nº de citas: 31

    [doi:10.1021/jm2007886]

  • Cardoso-Silva C, Barbería E, Ramos Atance JA, Maroto M, Hernández A, García-Godoy F.

    Microbiological analysis of gingivitis in pediatric patients under orthodontic treatment

    EUROPEAN JOURNAL OF PAEDIATRIC DENTISTRY . 12(4): 210-214. Nº de citas: 8

  • Tapia-González S, Giráldez-Pérez RM, Cuartero MI, Casarejos MJ, Mena MÁ, Wang XF, Sánchez-Capelo A.

    Dopamine and alpha- synuclein dysfunction in Smad3 null mice

    MOLECULAR NEURODEGENERATION . 6: 72-72. Nº de citas: 37

    [doi:10.1186/1750-1326-6-72]

  • Lafuente H, Alvarez FJ, Pazos MR, Alvarez A, Rey-Santano MC, Mielgo V, Murgia-Esteve X, Hilario E, Martinez-Orgado J.

    Cannabidiol Reduces Brain Damage and Improves Functional Recovery After Acute Hypoxia-Ischemia in Newborn Pigs

    PEDIATRIC RESEARCH . 70(3): 272-277. Nº de citas: 65

    [doi:10.1203/PDR.0b013e3182276b11]

  • Sagredo O, Pazos MR, Satta V, Ramos JA, Pertwee RG, Fernández-Ruiz J.

    Neuroprotective Effects of Phytocannabinoid-Based Medicines in Experimental Models of Huntington's Disease

    JOURNAL OF NEUROSCIENCE RESEARCH . 89(9): 1509-1518. Nº de citas: 62

    [doi:10.1002/jnr.22682]

  • Rubio M, Villain H, Docagne F, Roussel BD, Ramos JA, Vivien D, Fernandez-Ruiz J, Ali C.

    Pharmacological Activation/Inhibition of the Cannabinoid System Affects Alcohol Withdrawal-Induced Neuronal Hypersensitivity to Excitotoxic Insults

    Plos One . 6(8): . Nº de citas: 15

    [doi:10.1371/journal.pone.0023690]

  • Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gómez-Cañas M, Valdeolivas S, Guaza C, Romero J, Guzmán M, Mechoulam R, Ramos JA.

    Prospects for cannabinoid therapies in basal ganglia disorders

    BRITISH JOURNAL OF PHARMACOLOGY . 163(7, SI): 1365-1378. Nº de citas: 80

    [doi:10.1111/j.1476-5381.2011.01365.x]

  • García C, Palomo-Garo C, García-Arencibia M, Ramos J, Pertwee R, Fernández-Ruiz J.

    Symptom-relieving and neuroprotective effects of the phytocannabinoid Delta(9)-THCV in animal models of Parkinson's disease

    BRITISH JOURNAL OF PHARMACOLOGY . 163(7, SI): 1495-1506. Nº de citas: 124

    [doi:10.1111/j.1476-5381.2011.01278.x]

  • Jazwa A, Rojo AI, Innamorato NG, Hesse M, Fernández-Ruiz J, Cuadrado A.

    Pharmacological Targeting of the Transcription Factor Nrf2 at the Basal Ganglia Provides Disease Modifying Therapy for Experimental Parkinsonism

    ANTIOXIDANTS & REDOX SIGNALING . 14(12): 2347-2360. Nº de citas: 214

    [doi:10.1089/ars.2010.3731]

  • Casarejos MJ, Solano RM, Gómez A, Perucho J, de Yébenes JG, Mena MA.

    The accumulation of neurotoxic proteins, induced by proteasome inhibition, is reverted by trehalose, an enhancer of autophagy, in human neuroblastoma cells

    NEUROCHEMISTRY INTERNATIONAL . 58(4): 512-520. Nº de citas: 82

    [doi:10.1016/j.neuint.2011.01.008]